Pyridoxal isonicotinoyl hydrazone (PIH) and its analogs as protectants against anthracycline-induced cardiotoxicity

Hemoglobin

Volumn 32, Issue 1-2, 2008, Pages 207-215

  Simunek, Tomas ^a   Sterba, Martin ^b   Popelova, Olga ^b   Kaiserova, Helena ^a   Potacova, Anna ^b   Adamcova, Michaela ^b   Mazurova, Yvona ^b   Ponka, Premysl ^c   Gersl, Vladimir ^b  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Anthracycline cardiotoxicity; Cardioprotection; Iron chelation; Pyridoxal isonicotinoyl hydrazone (PIH); Pyridoxal o chlorbenzoyl hydrazone (o 108); Salicyladehyde isonicotinoyl hydrazone (SIH)

Indexed keywords

DAUNORUBICIN; HYDRAZONE DERIVATIVE; PYRIDOXAL ISONICOTINOYLHYDRAZONE; PYRIDOXAL O CHLORBENZOYL HYDRAZONE; SALICYLADEHYDE ISONICOTINOYL HYDRAZONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; CARDIOTOXICITY; CONFERENCE PAPER; CONTROLLED STUDY; DEATH; FUNCTIONAL DISEASE; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; MALE; MORTALITY; NONHUMAN; RABBIT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOTONIC AGENTS; DAUNORUBICIN; HEART DISEASES; IRON CHELATING AGENTS; ISONIAZID; PYRIDOXAL; RABBITS;

ORYCTOLAGUS CUNICULUS;

EID: 39349108153     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.1080/03630260701680276     Document Type: Conference Paper

References (21)

1. Hrdina R, Gersl V, Klimtova I, Simunek T, Machackova J, Adamcova M. Anthracycline-induced cardiotoxicity. Acta Medica (Hradec Kralove) 2000; 43(3):75-82.
2. Swain SM, Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol 2004; 130(1):1-7.
3. Hasinoff BB, Patel D, Wu X. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. Free Radic Biol Med 2003; 35(11):1469-1479.
4. Simunek T, Klimtova I, Kaplanova J, Mazurova Y, Adamcova M, Sterba M, Hrdina R, Gersl V. Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents. Eur J Heart Fail 2004; 6(4):377-387.
5. Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 2005; 57(4):547-583.
6. Kontoghiorghes GJ. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. Comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. Hemoglobin 2006; 30(2):329-347.
7. Hershko C, Link G, Tzahor M, Kaltwasser JP, Athias P, Grynberg A, Pinson A. Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture. J Lab Clin Med 1993; 122(3):245-251.
8. Voest EE, van Acker SA, van der Vijgh WJ, van Asbeck BS, Bast A. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity. J Mol Cell Cardiol 1994; 26(9):1179-1185.
9. Saad SY, Najjar TA, Al-Rikabi AC. The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Pharmacol Res 2001; 43(3):211-218.
10. Herman EH, Zhang J, Ferrans VJ. Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats. Cancer Chemother Pharmacol 1994; 35(2):93-100.
11. Barnabe N, Zastre JA, Venkataram S, Hasinoff BB. Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Free Radic Biol Med 2002; 33(2):266-275.
12. Xu LJ, Jin L, Pan H, Zhang AZ, Wei G, Li PP, Lu WY. Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin. Acta Pharmacol Sin 2006; 27(10):1333-1339.
13. Ponka P, Borova J, Neuwirt J, Fuchs O. Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett 1979; 97(2):317-321.
14. Simunek T, Boer C, Bouwman RA, Vlasblom R, Versteilen AM, Sterba M, Gersl V, Hrdina R, Ponka P, de Lange JJ, Paulus WJ, Musters RJ. SIH-a novel lipophilic iron chelator-protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death. J Mol Cell Cardiol 2005; 39(2):345-354.
15. Klimtova I, Simunek T, Gersl V, Hrdina R, Machackova J, Ponka P, Adamcova M, Palicka V. Biochemical and haematological changes following repeated pyridoxal isonicotinoyl hydrazone administration in rabbits. Biom Environ 2001; 4(Suppl 1):70-75.
16. Klimtova I, Simunek T, Mazurova Y, Kaplanova J, Sterba M, Hrdina R, Gersl V, Adamcova M, Ponka P. A study of potential toxic effects after repeated 10-week administration of a new iron chelator-salicylaldehyde isonicotinoyl hydrazone (SIH) to rabbits. Acta Medica (Hradec Kralove) 2003; 46(4):163-170.
17. Sterba M, Simunek T, Mazurova Y, Adamcova M, Popelova O, Kaplanova J, Ponka P, Gersl V. Safety and tolerability of repeated administration of pyridoxal 2-chlorobenzoyl hydrazone in rabbits. Hum Exp Toxicol 2005; 24(11):581-589.
18. Kwok JC, Richardson DR. Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway. Mol Pharmacol 2003; 63(4):849-861.
19. Kovarikova P, Mokry M, Klimes J, Vavrova K. HPLC study on stability of pyridoxal isonicotinoyl hydrazone. J Pharm Biomed Anal 2006; 40(1):105-112.
20. Kovarikova P, Klimes J, Sterba M, Popelova O, Mokry M, Gersl V, Ponka P. Development of high-performance liquid chromatographic determination of salicylaldehyde isonicotinoyl hydrazone in rabbit plasma and application of this method to an in vivo study. J Sep Sci 2005; 28(12):1300-1306.
21. Kovarikova P, Klimes J, Sterba M, Popelova O, Gersl V, Ponka P. HPLC determination of a novel aroylhydrazone iron chelator (o-108) in rabbit plasma and its application to a pilot pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 838(2):107-112.